Fresenius Medical Care Sees U.S. Plans for Kidney Disease as Positive
As a health professional, you need the leading dialysis products, renal pharmaceuticals and critical care solutions. Let's work together to find you the tools you need, so you can deliver the best care for patients.
Power your practice with our resources. We're here to help support your patients and your thriving practice.
Every day, we’re working tirelessly to transform the future of healthcare. Because every patient deserves treatment as strong as they are.
Browser Upgrade Recommended: Our website has detected that you are using a version of Internet Explorer that will prevent you from accessing certain features on FMCNA.com. We strongly recommend that you use a different browser to optimize your viewing experience. Supported browsers include Chrome, Edge, Firefox, and Safari.
We are actively monitoring the novel coronavirus (COVID-19) pandemic. Learn About the steps that we are taking to protect our patients, employees, physicians, and partners. If you are a patient with questions or concerns, please find additional information at FreseniusKidneyCare.com and AzuraVascularCare.com
Success! The link has been copied to your clipboard.
WALTHAM, MASS. – April 6, 2020 – Fresenius Medical Care North America (FMCNA), the nation’s leading provider of kidney care products and services, announced record growth of home therapies. The company also announced additional steps it has taken to expand telehealth and other technologies to support patients during the response to COVID-19, including:
The number of FMCNA patients on home dialysis, whether home hemodialysis (HHD) or peritoneal dialysis (PD), has increased almost 15 percent during the past year*, a record rate of growth in home modalities that is nine times the growth rate of patients treated in-center. Additionally, HHD has increased 40 percent in the past year, and the company saw a 25 percent increase in home trainings conducted in Q1 2020 compared to Q1 2019.
“Our success in growing home treatments is a direct result of our commitment to improving patient and physician education, and investing in technology to improve the home experience,” said Bill Valle, Chief Executive Officer of Fresenius Medical Care North America. “More than ever during this challenging time, the impact of home dialysis and telehealth technologies are clear. We are committed to ensuring that every patient who has the ability and desire to receive dialysis treatment at home has the opportunity to do so.”
As a result of a presidential executive order announced in July 2019, the Centers for Medicare and Medicaid Services (CMS) has encouraged the shift to home therapies. Since their merger with NxStage in February 2019, FMCNA has already achieved these additional home dialysis initiatives and milestones:
The company continues to offer meaningful, educational information to the public through its Fresenius Kidney Care patient-facing website and its Fresenius Medical Care North America website. For more details on the company’s response to COVID-19 visit here.
*Measured by the one year period from March 1, 2019 to March 1, 2020.
About Fresenius Medical Care North America
Fresenius Medical Care North America (FMCNA) is the premier healthcare company focused on providing the highest quality care to people with renal and other chronic conditions. Through its industry-leading network of dialysis facilities and outpatient cardiac and vascular labs, Fresenius Medical Care North America provides coordinated healthcare services at pivotal care points for hundreds of thousands of chronically ill customers throughout the continent. As the world’s largest fully integrated renal company, it offers specialty pharmacy and laboratory services, and manufactures and distributes the most comprehensive line of dialysis equipment, disposable products, and renal pharmaceuticals. For more information, visit the FMCNA website at https://fmcna.com.
Fresenius Medical Care North America